

Ozop Surgical Corp.

11:06 18 Mar 2019

Ozop rises as company gives vision for minimally invasive spinal surgery

Ozop Surgical Corp (OTCMKTS:OZSC) rose Monday as the surgical device company said it is moving forward with its plans to use medical-quality balloons in minimally invasive spinal surgery.

The company said expected 2019-2020 milestones include establishing a team of surgeons and other experts in the development of Balloon Lumbar Interbody Fusion (BLIF) technology.

Shares of Ozop climbed 6.3% to \$0.85 in Monday's OTC Markets trading.

READ: Ozop Surgical recognized as a top 10 orthopedic products provider by Med Tech Outlook magazine

Ozop is also expecting to complete all necessary testing for Food and Drug Administration (FDA) submission in the next two years. Upon approval, the company plans to build sets, complete a robust training regimen and begin "an alpha launch at key centers."

In 2018, the company said it began development of an enhanced expandable anterior lumbar interbody fusion (ALIF) implant with initial designs and prototypes completed.

The company expects to complete design and testing in the first half of 2019 and expects FDA approval in the second half.

"We are happy with our accomplishments to date and realize we have a lot of work ahead of us to achieve our goals and objectives for 2019 and beyond," CEO Michael Chermak said in a statement. "I thank all of our shareholders and investors for the confidence they have shown in our company."


He added that he looks forward to making "a significant impact" for people suffering from back pain as well as on the healthcare industry as a whole.

Contact Dennis Fitzgerald at dennis@proactiveinvestors.com

Price: US\$0.12

Market Cap: US\$3.83M

1 Year Share Price Graph



October 2018 March 2019 May 2019

Share Information

Code: OZSC

Listing: OTCMKTS

52 week High Low
\$2.10 \$0.05

Sector: Health Care, Equipment & Services

Website: ozopsurgical.com

Company Synopsis:

Ozop Surgical Corp. invents, designs, develops, manufactures and globally distributes innovative endoscopic instruments, surgical implants, instrumentation, devices and related technologies, focused on spine, neurological and pain management procedures and specialties.

Author:

Proactive Investors Ltd

+44 (0)207 989 0813

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

Proactive Investors is a publisher and is not registered with or authorised by the Financial Conduct Authority (FCA). You understand and agree that no content published constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.